- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Genetic Aspects of Alzheimer Disease
The panel provides an overview of genetic factors associated with Alzheimer disease and the genetic mutations that contribute to the pathophysiology of the disease.
EP: 1.The Clinical and Economic Implications of Alzheimer Disease Across Patients, Families, and the Health Care System
EP: 2.Recent Insights into the Pathophysiology of Alzheimer Disease
EP: 3.Genetic Aspects of Alzheimer Disease
EP: 4.The Patient Experience: From Symptoms to Diagnosis of Alzheimer Disease
EP: 5.Potential Consequences of Early Diagnosis of Alzheimer Disease
EP: 6.Criteria for Diagnosing Alzheimer Disease and the Role of Testing
EP: 7.Exploring the Economic Impact of Advanced Approaches for Diagnosing Alzheimer Disease
EP: 8.Clinical Impact of the Introduction of Disease-Modifying Treatments for Alzheimer Disease
EP: 9.Clinical Decision-Making for Alzheimer Disease Management
EP: 10.Cost, Value, and Affordability of Treatment for Alzheimer Disease
EP: 11.Advancements in Alzheimer Disease Treatment: Emerging Drug Candidates
EP: 12.Exploring the Influence of Administration Routes on Medical Costs and Caregiver Burden
EP: 13.Payer Coverage Considerations for New Treatments for Alzheimer Disease
EP: 14.Concluding Remarks: Impact of Alzheimer Disease, Promising Treatments in Development, and Future Outlook
- [Dr Snider] Discuss the genetic factors associated with AD. How do mutations in genes such as APP, PSEN1, and PSEN2 contribute to the pathophysiology of the disease? How do different alleles of APOE4affect risk of developing AD?
High HSP60 Expression Signals Poor Prognosis, Aggressive Tumors in Ovarian Cancer
January 16th 2025High heat shock protein 60 (HSP60) expression in patients with ovarian cancer is associated with larger tumors, advanced stages, and worse survival outcomes, highlighting its potential as a prognostic biomarker.
Read More
Real-World Evidence Confirms the Benefits of JAK Inhibitors in Patients With Rheumatoid Arthritis
January 16th 2025This systematic review of real-world observational studies demonstrated the effectiveness of Janus kinase (JAK) inhibitors in improving treatment adherence, persistence, clinical outcomes, and patient-reported outcomes among US patients with rheumatoid arthritis.
Read More
